Samsung-owned healthcare company Neurologica receives Food and Drug Administration (FDA) clearance for its new artificial intelligence technology named Auto Lung Nodule Detection (ALND) that detects lung nodules in chest X-rays.
The new technology provides on-device computer-assisted detection of pulmonary nodules from 10mm to 30mm in size. The solution uses artificial intelligence algorithms to generate reports.
This technology will drastically help doctors and healthcare professionals to diagnose and identify issues and take quick measures while treating patients. The solution has already been tested in several academic centers, and it shows a sensitivity of over 80% for detecting pulmonary lung nodules.
Vice President of digital radiography and ultrasound at Neurologica, David Legg, said, “This FDA clearance is a huge milestone for Samsung and is the result of our tireless work to design diagnostic solutions that empower providers to deliver patients the absolute best care possible.”
He further added that the technology’s accuracy and reliability would allow doctors to present it in front of patients with utmost confidence. The technology also comes with an autorun option that automatically starts processing images after X-ray and offers a PACS transmission option to suit hospital environments. However, the tool cannot be used on patients with lung lesions other than abnormal nodules.
United States-based medical imaging equipment manufacturing firm Neurologica was founded by Ibrahim Bechwati in 2004. The company had raised over $17 million in two funding rounds before being acquired by Samsung in 2013. Neurologica specializes in developing healthcare equipment that helps doctors and hospitals to provide better patient experience, patient care, patient satisfaction and also optimize hospital workflow.